These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31280643)

  • 1. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.
    Garabet L; Ghanima W; Monceyron Jonassen C; Skov V; Holst R; Mowinckel MC; C Hasselbalch H; A Kruse T; Thomassen M; Liebman H; Bussel JB; Sandset PM
    Platelets; 2019; 30(2):206-212. PubMed ID: 29215956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists.
    Justo Sanz R; Monzón Manzano E; Fernández Bello I; Teresa Álvarez Román M; Martín Salces M; Rivas Pollmar MI; Jiménez Yuste V; Butta NV
    Thromb Haemost; 2019 Apr; 119(4):645-659. PubMed ID: 30743272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
    Qu MM; Liu XN; Liu XG; Feng Q; Liu Y; Zhang X; Liu S; Zhang L; Li GS; Zhu YY; Lv MY; Peng J; Hou M
    Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists.
    Garabet L; Henriksson CE; Lozano ML; Ghanima W; Bussel J; Brodin E; Fernández-Pérez MP; Martínez C; González-Conejero R; Mowinckel MC; Sandset PM
    Thromb Res; 2020 Jan; 185():119-124. PubMed ID: 31805421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists regulate myeloid-derived suppressor cell-mediated immunomodulatory effects in ITP.
    Zhu Y; Wang Y; Zhao Y; Liu D; Wang X; Zhu L; Tong J; Zhao N; Zheng C
    Ann Hematol; 2024 Aug; 103(8):2729-2741. PubMed ID: 38890176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
    van Dijk WEM; Poolen GC; Huisman A; Koene HR; Fijnheer R; Thielen N; van Bladel ER; van Galen KPM; Schutgens REG; Urbanus RT
    J Thromb Haemost; 2023 Apr; 21(4):1020-1031. PubMed ID: 36696209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.
    Garabet L; Ghanima W; Rangberg A; Teruel-Montoya R; Martinez C; Lozano ML; Nystrand CF; Bussel JB; Sandset PM; Jonassen CM
    Platelets; 2020; 31(2):198-205. PubMed ID: 30885035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.